Trials / Completed
CompletedNCT01184976
Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- GeneOne Life Science, Inc. · Industry
- Sex
- Male
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
Research Hypothesis: VGX-3400 (DNA plasmids encoding the hemagglutinin (HA), neuraminidase (NA), and M2e-NP antigen of the H5N1 avian influenza virus) administered to healthy adult males by IM injection followed by EP will be generally well tolerated and immunogenic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VGX-3400 | Plasmid DNA delivered via IM injection with electroporation |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-08-19
- Last updated
- 2015-03-17
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01184976. Inclusion in this directory is not an endorsement.